Year of publication: 2022

CPNP 2022

Antipsychotic Efficacy of KarXT (Xanomeline–Trospium): Analysis of Positive and Negative Syndrome Scale Categorial Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study

ECNP 2022

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Patients With Schizophrenia: Results From a Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial (EMERGENT-2)

NEI 2022

Safety and Efficacy of KarXT (Xanomeline–Trospium) in Schizophrenia in the Phase 3, Randomized, Double-Blind, Placebo-Controlled EMERGENT-2 Trial

Antipsychotic Efficacy of KarXT (Xanomeline−Trospium): Post Hoc Analysis of Positive and Negative Syndrome Scale Categorical Response Rates, Time Course of Response, and Symptom Domains of Response in a Phase 2 Study

Weiden PJ, et al. Antipsychotic efficacy of KarXT (xanomeline-trospium): post hoc analysis of positive and negative syndrome scale categorical response rates, time course of response, and symptom domains of response in a phase 2 study. J Clin Psychiatry. 2022;83(3):21m14316.

SIRS 2022

The Muscarinic Agonist Xanomeline Demonstrates Standalone Activity and Augments Clinical Antipsychotics in Rodent Behavioral Models of Psychosis

SIRS 2022

Acetylcholine as a Regulator of Dopamine Pathways: Rationale for Selective Muscarinic Agonists as Candidates for Antipsychotic Drug Development